HRP20160280T1 - Uporaba vaginalno primijenjenih sredstava koja povećavaju osjetljivost na inzulin - Google Patents
Uporaba vaginalno primijenjenih sredstava koja povećavaju osjetljivost na inzulin Download PDFInfo
- Publication number
- HRP20160280T1 HRP20160280T1 HRP20160280TT HRP20160280T HRP20160280T1 HR P20160280 T1 HRP20160280 T1 HR P20160280T1 HR P20160280T T HRP20160280T T HR P20160280TT HR P20160280 T HRP20160280 T HR P20160280T HR P20160280 T1 HRP20160280 T1 HR P20160280T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- day
- metformin
- prevention
- treatment
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title claims 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 230000001235 sensitizing effect Effects 0.000 title 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 7
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 5
- 229960003105 metformin Drugs 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 3
- 206010020112 Hirsutism Diseases 0.000 claims 3
- 206010036049 Polycystic ovaries Diseases 0.000 claims 3
- 206010000496 acne Diseases 0.000 claims 3
- 208000024963 hair loss Diseases 0.000 claims 3
- 230000003676 hair loss Effects 0.000 claims 3
- 208000000509 infertility Diseases 0.000 claims 3
- 230000036512 infertility Effects 0.000 claims 3
- 231100000535 infertility Toxicity 0.000 claims 3
- 230000001788 irregular Effects 0.000 claims 3
- 230000027758 ovulation cycle Effects 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033307 Overweight Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 201000010066 hyperandrogenism Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Uporaba barem jednog sredstva koje povećava osjetljivost na inzulin u pripremi farmaceutskog pripravka za prevenciju i/ili liječenje hiperandrogenizma i/ili sindroma policističnih jajnika i/ili barem jednog povezanog poremećaja iz skupine koju čine: hirzutizam, akne, gubitak kose, prekomjerna težina, pretilost, nepravilni, sporadični ili izostali menstrualni ciklusi, povećani i/ili policistični jajnici i neplodnost; pri čemu se taj pripravak primjenjuje vaginalno.
2. Uporaba prema zahtjevu 1, za prevenciju i/ili liječenje sindroma policističnih jajnika.
3. Uporaba prema zahtjevu 1, za prevenciju i/ili liječenje nepravilnih, sporadičnih ili izostalih menstrualnih ciklusa, povećanih i/ili policističnih jajnika i/ili neplodnosti povezanih sa sindromom policističnih jajnika.
4. Uporaba prema zahtjevu 1, za prevenciju i/ili liječenje hirzutizma, akni i/ili gubitka kose povezanih s hiperandrogenim stanjima.
5. Uporaba prema bilo kojem od zahtjeva 1 do 4, gdje sredstvo koje povećava osjetljivost na inzulin jest metformin ili jedna od njegovih farmaceutski prikladnih soli, hidrata ili polimorfa.
6. Uporaba prema zahtjevu 5, gdje je doza metformina u rasponu između 0.01 mg/dan i 1000 mg/dan.
7. Uporaba prema zahtjevu 6, gdje je doza metformina u rasponu između 0.1 mg/dan i 100 mg/dan.
8. Uporaba prema zahtjevu 7, gdje je doza metformina u rasponu između 0.5 mg/dan i 50 mg/dan.
9. Uporaba prema zahtjevu 8, gdje je doza metformina u rasponu između 1 mg/dan i 10 mg/dan.
10. Uporaba prema bilo kojem od zahtjeva 1 do 4, gdje sredstvo koje povećava osjetljivost na inzulin jest tiazolidindion ili jedna od njegovih farmaceutski prikladnih soli, hidrata ili polimorfa.
11. Farmaceutski pripravak koji sadrži barem jedno sredstvo koje povećava osjetljivost na inzulin za uporabu u prevenciji i/ili liječenju hiperandrogenizma i/ili sindroma policističnih jajnika i/ili barem jednog povezanog poremećaja iz skupine koju čine: hirzutizam, akne, gubitak kose, prekomjerna težina, pretilost, nepravilni, sporadični ili izostali menstrualni ciklusi, povećani i/ili policistični jajnici i neplodnost; pri čemu se taj farmaceutski pripravak primjenjuje vaginalno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200900448A ES2344183B1 (es) | 2009-02-18 | 2009-02-18 | Uso de agentes sensibilizantes a insulina por via vaginal. |
| EP10743433.4A EP2399583B1 (en) | 2009-02-18 | 2010-02-16 | Use of vaginally-administered insulin sensitizing agents |
| PCT/ES2010/000067 WO2010094821A1 (es) | 2009-02-18 | 2010-02-16 | Uso de agentes sensibilizantes a insulina por vía vaginal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160280T1 true HRP20160280T1 (hr) | 2016-06-17 |
Family
ID=42537373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160280TT HRP20160280T1 (hr) | 2009-02-18 | 2016-03-18 | Uporaba vaginalno primijenjenih sredstava koja povećavaju osjetljivost na inzulin |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120004271A1 (hr) |
| EP (1) | EP2399583B1 (hr) |
| BR (1) | BRPI1005950A2 (hr) |
| CY (1) | CY1117425T1 (hr) |
| DK (1) | DK2399583T3 (hr) |
| ES (2) | ES2344183B1 (hr) |
| HR (1) | HRP20160280T1 (hr) |
| HU (1) | HUE027369T2 (hr) |
| PL (1) | PL2399583T3 (hr) |
| RU (1) | RU2567334C2 (hr) |
| SI (1) | SI2399583T1 (hr) |
| SM (1) | SMT201600101B (hr) |
| WO (1) | WO2010094821A1 (hr) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478852C1 (en) * | 1993-09-15 | 2001-03-13 | Sankyo Co | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus |
| US5874454A (en) * | 1993-09-15 | 1999-02-23 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
| FR2774591B1 (fr) * | 1998-02-12 | 2000-05-05 | Lipha | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
| US6100300A (en) * | 1998-04-28 | 2000-08-08 | Bristol-Myers Squibb Company | Metformin formulations and method for treating intermittent claudication employing same |
| RU2201225C2 (ru) * | 1999-04-06 | 2003-03-27 | Зыкова Татьяна Алексеевна | Способ лечения хронической ановуляции и профилактики синдрома гиперстимуляции яичников |
| US7105489B2 (en) * | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| MXPA04007713A (es) * | 2002-02-07 | 2004-11-10 | Pfizer | Uso de inhibidores de la fosfodiesterasa tipo 5, tal como sildenafil, en el tratamiento del sindrome de ovario poliquistico. |
| WO2003068209A1 (en) * | 2002-02-14 | 2003-08-21 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
-
2009
- 2009-02-18 ES ES200900448A patent/ES2344183B1/es active Active
-
2010
- 2010-02-16 US US13/201,991 patent/US20120004271A1/en not_active Abandoned
- 2010-02-16 BR BRPI1005950A patent/BRPI1005950A2/pt not_active Application Discontinuation
- 2010-02-16 EP EP10743433.4A patent/EP2399583B1/en active Active
- 2010-02-16 ES ES10743433.4T patent/ES2569538T3/es active Active
- 2010-02-16 SI SI201031169A patent/SI2399583T1/sl unknown
- 2010-02-16 RU RU2011135702/15A patent/RU2567334C2/ru active
- 2010-02-16 WO PCT/ES2010/000067 patent/WO2010094821A1/es active Application Filing
- 2010-02-16 DK DK10743433.4T patent/DK2399583T3/en active
- 2010-02-16 PL PL10743433.4T patent/PL2399583T3/pl unknown
- 2010-02-16 HU HUE10743433A patent/HUE027369T2/hu unknown
-
2016
- 2016-03-18 HR HRP20160280TT patent/HRP20160280T1/hr unknown
- 2016-04-11 CY CY20161100287T patent/CY1117425T1/el unknown
- 2016-04-12 SM SM201600101T patent/SMT201600101B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2399583B1 (en) | 2016-01-27 |
| ES2344183A1 (es) | 2010-08-19 |
| PL2399583T3 (pl) | 2016-09-30 |
| ES2569538T3 (es) | 2016-05-11 |
| BRPI1005950A2 (pt) | 2016-02-10 |
| HUE027369T2 (hu) | 2016-09-28 |
| WO2010094821A1 (es) | 2010-08-26 |
| EP2399583A1 (en) | 2011-12-28 |
| ES2344183B1 (es) | 2011-06-10 |
| US20120004271A1 (en) | 2012-01-05 |
| SMT201600101B (it) | 2016-07-01 |
| RU2567334C2 (ru) | 2015-11-10 |
| RU2011135702A (ru) | 2013-03-27 |
| EP2399583A4 (en) | 2012-08-15 |
| DK2399583T3 (en) | 2016-04-18 |
| SI2399583T1 (sl) | 2016-06-30 |
| CY1117425T1 (el) | 2017-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140854A1 (es) | Formas de dosificacion farmaceutica | |
| RS53876B1 (en) | PARENTERAL PHARMACEUTICAL FORM, WHICH RELEASES AROMATASE AND GESTAGEN BLOCKERS, FOR THE TREATMENT OF ENDOMETRIOSIS | |
| HRP20240317T1 (hr) | Liječenje hepatičke encefalopatije uporabom rifaksimina | |
| HRP20160436T1 (hr) | Derivati glikozida i njihove uporabe | |
| GB2448224B (en) | Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| BRPI0917540A2 (pt) | composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável | |
| UY30107A1 (es) | Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones | |
| WO2011079239A3 (en) | Combination tablet with chewable outer layer | |
| JP2009526087A5 (hr) | ||
| BRPI0818193A2 (pt) | composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto | |
| CL2008000133A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e | |
| CL2011003291A1 (es) | Composicion farmaceutica de dosis unica que contiene a) como gestageno 50-90 µg de levonorgestrel y b) como inhibidor cox (ciclooxigenasa) 5-60 mg de piroxicam, 50-600 mg de indometacina o 40-450 mg de diclofenaco; y su uso para preparar medicamentos para la anticoncepcion en caso de emergencia. | |
| AR078417A1 (es) | Composiciones de pelicula sublingual y bucal | |
| JP2008543936A5 (hr) | ||
| NZ588913A (en) | Liver cancer drug | |
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| CL2007000345A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes. | |
| AR077284A1 (es) | Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica | |
| JP2009537554A5 (hr) | ||
| WO2007143163A3 (en) | Pharmaceutical compositions for sustained release of phenyephrine | |
| BR112013006597A2 (pt) | tablete para desintegração oral em múltiplas camadas, e a fabricação do mesmo | |
| AR077546A1 (es) | Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos | |
| ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| IL210544A (en) | Pharmaceuticals containing pyrazole derivatives, solid oral dosage forms containing them and their uses for drug preparation |